| Prev Close | 0.81 |
| Open | 0.81 |
| Day Low/High | 0.70 / 0.83 |
| 52 Wk Low/High | 1.62 / 4.27 |
| Volume | 44.84K |
| Avg Volume | 94.00K |
| Exchange | NASDAQ |
| Shares Outstanding | 16.24M |
| Market Cap | 12.99M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK
Clinically validated BREVAGenplus(R) more accurately identifies sporadic breast cancer risk
ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK
Personalized, Genetically-Based Test Enables Physicians to Tailor Breast Cancer Screening and Reduction Services Based on Individual Risk
5 Stocks Ready for Breakouts
These stocks look poised to break out and trade higher from current levels.
Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test
Shares of Genetic Technologies Ltd. (GENE) rose Monday after the molecular diagnostics company announced that two new breast health centers will start to offer BREVAGenplus®.
PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT
Findings presented at the 2014 San Antonio Breast Cancer Symposium
Why Genetic Technologies (GENE) Stock Is Spiking Today
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
5 Stocks Ready for Breakouts
These stocks look poised to break out and trade higher from current levels.
Interesting GENE Call For February 2014
Investors in Genetic Technologies Ltd. saw new options become available today, for the February 2014 expiration.
STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE
Phenogen Sciences, Inc. Presented Study Results at the 23rd Annual National Interdisciplinary Breast Center Conference
The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment
Local Physician One of the First in Nation to Use New Breast Cancer Predictive Risk Test
5 Stocks Ready to Break Out
These stocks look poised to break out and trade higher from current levels.
4 Stocks Under $10 Making Big Moves
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
4 Biotech Stocks Under $10 Soaring Higher
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BREVAGen Reclassified 64% Of Intermediate Gail Risk Subjects(1) (Graphic: Business Wire)
Dr. Owen Winsett of the Breast Center of Austin is one of the first physicians in the nation to make the BREVAGen™ predictive risk test available to his patients.
8 Stocks Under $10 Ripping Higher
When a stock makes a large percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Genetic Technologies Limited Announces Quarterly Activities Report For The Quarter Ended 30 September 2011
Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) today reported their quarterly activities report for the quarter ended 30 September, 2011.
Genetic Technologies’ BREVAGen™ Changing The Way US Physicians Assess Breast Cancer Risk
Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) today reported early insights from the US regional launch of BREVAGen™, its new, easy-to-use, predictive risk test for the tens of millions of women at ...
Genetic Technologies Limited Appoints Dr. Mervyn Cass As Company Director
The Board of Directors of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has with great pleasure appointed Dr.
Optimer Soars on Antibiotic Data
Optimer Pharmaceuticals proves that even in a bear market, small biotech stocks are still capable of doubling in price overnight.
Ties May Bind Apple's CEO to Board
Analysts ponder the state of independence of a board handpicked by Steve Jobs.
